Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

• المؤلفون الرئيسيون: Riccardo G. Borroni (مؤلف), Piergiorgio Malagoli (مؤلف), Luigi Gargiulo (مؤلف), Mario Valenti (مؤلف), Giulia Pavia (مؤلف), Paola Facheris (مؤلف), Emanuela Morenghi (مؤلف), Isotta Giunipero di Corteranzo (مؤلف), Alessandra Narcisi (مؤلف), Michela Ortoncelli (مؤلف), Paolo Dapavo (مؤلف), Antonio Costanzo (مؤلف)
• التنسيق: كتاب
• منشور في: Medical Journals Sweden, 2021-11-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...